Deletion of the CYP2D6 gene as a likely explanation for the serious side effects of the antipsychotic drug pimozide: a case report
CYP2D6 analysis prior to the prescription of pimozide is required above a certain dose by the Food and Drug Administration in order to detect individuals with the poor metabolizer status. This precautionary measure aims to prevent the occurrence of serious adverse drug reactions. This study presents...
Main Authors: | Fernando Facal, Begoña Portela, Almudena Gil-Rodríguez, Francisco Barros, Olalla Maroñas, Angel Carracedo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1237446/full |
Similar Items
-
Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021-06-01) -
The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?
by: Ana Rita Simões, et al.
Published: (2020-11-01) -
Pimozide-induced tardive dyskinesia in the treatment of delusions of infestation
by: Rodrigo A. Gutierrez, BS, et al.
Published: (2024-03-01) -
The antipsychotic drug pimozide promotes apoptosis through the RAF/ERK pathway and enhances autophagy in breast cancer cells
by: Ge Jiang, et al.
Published: (2024-12-01) -
Fabrication and physicochemical characterisation of novel pimozide loaded PLGA nanoparticles
by: Ahmed M Faheem, et al.
Published: (2019-04-01)